MX2014002731A - Forma polimorfica de clorhidrato de pridopidina. - Google Patents

Forma polimorfica de clorhidrato de pridopidina.

Info

Publication number
MX2014002731A
MX2014002731A MX?A MX2014002731A MX2014002731A MX 2014002731 A MX2014002731 A MX 2014002731A MX 2014002731 A MX2014002731 A MX 2014002731A MX 2014002731 A MX2014002731 A MX 2014002731A
Authority
MX
Mexico
Prior art keywords
polymorphic form
pridopidine
pridopidine hydrochloride
hydrochloride
polymorphic
Prior art date
Application number
MX?A
Other languages
English (en)
Other versions
MX343620B (es
Inventor
Clas Sonesson
Thomas Pittelkow
Brian Frostrup
Anne Zimmermann
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of MX2014002731A publication Critical patent/MX2014002731A/es
Publication of MX343620B publication Critical patent/MX343620B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached

Abstract

Esta invención se refiere a una nueva forma cristalina de Pridopidina, una sustancia de fármaco actualmente en desarrollo para el tratamiento de la enfermedad de Huntington. Más específicamente la invención proporciona una Forma II polimórfica de la sal de clorhidrato de Pridopidina, un proceso para la preparación de esta forma polimórfica, composiciones farmacéuticas que comprenden la Forma II polimórfica y métodos de uso de esta forma polimórfica.
MX2014002731A 2011-09-07 2012-09-06 Forma polimorfica de clorhidrato de pridopidina. MX343620B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201170496 2011-09-07
US201161533550P 2011-09-12 2011-09-12
PCT/EP2012/067371 WO2013034622A1 (en) 2011-09-07 2012-09-06 Polymorphic form of pridopidine hydrochloride

Publications (2)

Publication Number Publication Date
MX2014002731A true MX2014002731A (es) 2014-04-30
MX343620B MX343620B (es) 2016-11-11

Family

ID=47831564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002731A MX343620B (es) 2011-09-07 2012-09-06 Forma polimorfica de clorhidrato de pridopidina.

Country Status (15)

Country Link
US (1) US9006445B2 (es)
EP (1) EP2753603B1 (es)
JP (2) JP6189299B2 (es)
KR (1) KR20140075703A (es)
CN (1) CN103958469B (es)
AU (1) AU2012306386B2 (es)
BR (1) BR112014005389A8 (es)
CA (1) CA2847736A1 (es)
EA (1) EA023462B1 (es)
ES (1) ES2639052T3 (es)
HK (1) HK1199728A1 (es)
IL (1) IL231149A0 (es)
MX (1) MX343620B (es)
WO (1) WO2013034622A1 (es)
ZA (1) ZA201402492B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
CN105592848A (zh) * 2013-06-21 2016-05-18 梯瓦制药国际有限责任公司 高剂量普利多匹定用于治疗亨廷顿舞蹈症的用途
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) * 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
AR105434A1 (es) * 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) * 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
AU2017223838B2 (en) 2016-02-24 2022-09-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
EP3504187A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. USE OF PRIDOPIDINE FOR THE TREATMENT OF FUNCTIONAL DECLINE
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
EP3357909A1 (en) 2017-02-02 2018-08-08 Sandoz AG Crystalline 4-[3-(methylsulfonyl)phenyl]-1-propyl-piperidine
FI3668509T3 (fi) 2017-08-14 2023-03-14 Prilenia Neurotherapeutics Ltd Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla
CA3073568A1 (en) 2017-08-30 2019-03-07 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
MX2020002645A (es) 2017-09-08 2021-06-10 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GB0329236D0 (en) * 2003-12-17 2004-01-21 Arakis Ltd Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride
ES2346452T3 (es) 2004-06-08 2010-10-15 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Nuevas fenilpiperidinas/piperazinas disustituidas utilizadas como moduladores de la neurotransmision de la dopamina.
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
MX2009011020A (es) 2007-04-12 2009-10-30 Nsab Af Neurosearch Sweden Ab Derivados de n-oxido y/o di-n-oxido de los estabilizadores/modulad ores del receptor de dopamina que exhiben perfiles mejorados de los efectos secundarios cardiovasculares.
EP2170327B1 (en) 2007-06-18 2014-10-22 A.Carlsson Research AB Use of dopamine stabilizers
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UY34503A (es) 2011-12-08 2013-07-31 Ivax Int Gmbh ?sal de bromhidrato de pridopidina?
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EA201590654A1 (ru) 2012-09-27 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
AU2013323131A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders

Also Published As

Publication number Publication date
CN103958469A (zh) 2014-07-30
NZ623344A (en) 2015-10-30
HK1199728A1 (en) 2015-07-17
JP2014525470A (ja) 2014-09-29
AU2012306386A1 (en) 2014-04-17
KR20140075703A (ko) 2014-06-19
US20140315951A1 (en) 2014-10-23
WO2013034622A1 (en) 2013-03-14
US9006445B2 (en) 2015-04-14
IL231149A0 (en) 2014-04-30
EP2753603B1 (en) 2017-06-21
BR112014005389A2 (pt) 2017-03-28
CA2847736A1 (en) 2013-03-14
EA023462B1 (ru) 2016-06-30
BR112014005389A8 (pt) 2018-04-03
JP2017206516A (ja) 2017-11-24
JP6189299B2 (ja) 2017-08-30
EP2753603A1 (en) 2014-07-16
CN103958469B (zh) 2016-04-20
ES2639052T3 (es) 2017-10-25
AU2012306386B2 (en) 2017-06-15
MX343620B (es) 2016-11-11
EA201490569A1 (ru) 2014-09-30
ZA201402492B (en) 2015-07-29

Similar Documents

Publication Publication Date Title
MX343620B (es) Forma polimorfica de clorhidrato de pridopidina.
IN2014KN00948A (es)
PH12015500460A1 (en) Coated pharmaceutical composition containing regorafenib
IL218257A0 (en) Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating uses thereof
MY149731A (en) Compounds
EA201491028A8 (ru) Способ получения замещенных 5-фтор-1н-пиразолопиридинов
HK1197414A1 (zh) 雌甾- -四烯- -甲酰胺衍生物、其製備方法、包含其的藥物製劑及其用於製備藥物的用途
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
MX2013012588A (es) Inhibidores de cinasa.
MX2014004196A (es) Citramida de rasagilina.
MX2013013465A (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
IN2013DN02555A (es)
ATE500226T1 (de) Aripiprazolhemifumarat und verfahren zu dessen herstellung
BR112013007904A2 (pt) "composto, composição farmacêutica, medicamento, uso de um composto e proceso para preparar um composto"
TN2015000095A1 (en) Macrolide derivatives, preparation thereof and therapeutic use thereof
EP2746284A4 (en) SALT AND POLYMORPH OF A PYRAZOLOPYRIMIDINONE COMPOUND AND ACTIVE COMPOSITION, PROCESS FOR THEIR PREPARATION AND THEIR USE
EP2752202A4 (en) PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES, COMPOSITION FOR PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES, AND PROCESS FOR PRODUCTION OF PHARMACEUTICAL PREPARATION FOR MOLLE CAPSULES
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
EP2766369A4 (en) NOVEL SALT OF SITAGLIPTIN, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION THEREOF
EP2789604A4 (en) DAZEZE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT AND METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
IN2014DN10683A (es)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: GILEAD SCIENCES, INC.

FG Grant or registration